14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VNDA vs CYTK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Cytokinetics Inc. (CYTK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas CYTK carries 57.6/100 (HOLD) at $53.18 (117.7x Forward P/E, -625.2% operating margin).
Composite vs. Pillar Nuance: While CYTK currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. VNDA 49.0/100 HOLD), VNDA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-77.6% vs. -625.2% operating margin) and revenue trajectory (+24.1% vs. +2356.5% YoY).
Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile CYTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $7.8B market capitalization and -625.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VNDA vs CYTK Key Questions & Quantitative Answers
As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Cytokinetics Inc. (CYTK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas CYTK carries 57.6/100 (HOLD) at $53.18 (117.7x Forward P/E, -625.2% operating margin). Composite vs. Pillar Nuance: While CYTK currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. VNDA 49.0/100 HOLD), VNDA captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-77.6% vs. -625.2% operating margin) and revenue trajectory (+24.1% vs. +2356.5% YoY). Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile CYTK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CYTK leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with CYTK at +2356.5% YoY revenue growth and +0.0% YoY earnings growth on $113M TTM revenue (N/A gross margin, -625.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while CYTK shifted +200.0%. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CYTK.
VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas CYTK trades at 117.7x Forward P/E, 117.7x Trailing P/E, N/M PEG, and 78.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus CYTK (-572.1% ROE) capital efficiency.
In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, CYTK carries 68.8% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.09β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.